PCSK9 Forum is made possible thanks to support from AstraZeneca, LIB Therapeutics, Novartis and Sanofi, all of whom have no influence or control over editorial content. More information is available here »

Already a member? Become a member Register
PCSK9 Forum

rss LinkedIn News
rss LinkedIn Latest News Updates

Webcasts


Play PCSK9 Inhibitors for Treatment of High Cholesterol levels: Effectiveness and Value
PCSK9 Inhibitors for Treatment of High Cholesterol levels: Effectiveness and Value
Play Lipoprotein-associated PCSK9: Physiological implications?
Sergio Fazio Lipoprotein-associated PCSK9: Physiological implications?
Play Legacy effects: Does early intensive LDL lowering treatment modify the atherosclerotic process?
Chris Packard Legacy effects: Does early intensive LDL lowering treatment modify the atherosclerotic process?
Play ApoB-containing lipoproteins and the pathophysiology of atherosclerotic vascular disease: update
Jan Boren ApoB-containing lipoproteins and the pathophysiology of atherosclerotic vascular disease: update
Play Innovative PCSK9-targeted therapeutics: siRNA
Steve Nicholls Innovative PCSK9-targeted therapeutics: siRNA
Play Monoclonal Antibodies: New options for diagnosis and therapy in CVD
Dario Neri Monoclonal Antibodies: New options for diagnosis and therapy in CVD
Play Imaging of atherosclerotic vascular disease: The challenges and impact of therapy
Raimund Erbel Imaging of atherosclerotic vascular disease: The challenges and impact of therapy
Play Very low LDL: Mechanism and potential clinical impact
Eran Leitersdorf Very low LDL: Mechanism and potential clinical impact
Play PCSK9 Clinical trials: What’s new?
Michel Farnier PCSK9 Clinical trials: What’s new?
Play PCSK9: What do we still need to know about its biology and therapeutic applications
Nabil G. Seidah PCSK9: What do we still need to know about its biology and therapeutic applications
Play Genotypic and phenotypic variation in FH – relevance to cardiovascular risk
Frederick J. Raal Genotypic and phenotypic variation in FH – relevance to cardiovascular risk
Play Statin Intolerance: What is it? What are therapeutic options?
Erik Stroes Statin Intolerance: What is it? What are therapeutic options?
Play A view from North America
Henry Ginsberg A view from North America
Play PCSK9 monoclonal antibody therapy: pharmacodynamics, efficacy and safety
Evan Stein PCSK9 monoclonal antibody therapy: pharmacodynamics, efficacy and safety
Play Mechanistic insights from PCSK9 LOF mutations
Anne Tybjaerg-Hansen Mechanistic insights from PCSK9 LOF mutations
Play How can we optimise PCSK9-targeted therapies?
Lluís Masana How can we optimise PCSK9-targeted therapies?
Play Evidence for the effects of PCSK9 beyond the liver
Bertrand Cariou Evidence for the effects of PCSK9 beyond the liver

About PCSK9 Education and Research Forum

PCSK9 Education and Research Forum is a not-for-profit organisation established by leading researchers in the fields of atherosclerosis, lipids and cardiovascular disease. Our mission is to raise awareness and knowledge of the significant role played by PCSK9 in lipid metabolism and its value as a novel therapeutic target.

Editorial Policy

Unless otherwise indicated, opinions expressed in the PCSK9 Education and Research Forum are those of the contributors. All patients should discuss their medication with their healthcare professional. Although every effort is made to ensure accuracy and avoid mistakes, no liability on the part of the PCSK9 Forum, the editors or the editorial board is accepted for the consequences of any misleading or inaccurate information.
Educational Partners and Supporters
AstraZeneca

AstraZeneca has provided a grant towards this independent project and has had no involvement in its creation or organisation

LIB Therapeutics

Novartis

Sanofi

© Copyright 2025 PCSK9 Forum. All rights reserved